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Therapeutic hypothermia (TH) is nowadays one of the most important methods of neuroprotection. 
The events that occur after an episode of ischemia are multiple and hypothermia can affect 
the various steps of this cascade. The mechanisms of action of TH are varied and the possible 
explanation for the benefits of this therapy is probably the multiple mechanisms of action blocking 
the cascade of ischemia on many levels. TH can affect many metabolic pathways, reactions of 
inflammation, apoptosis processes, and promote neuronal integrity. To know the mechanisms 
of action of TH will allow a better understanding about the indications for this therapy and the 
possibility of searching for other therapies when used in conjunction with hypothermia will 
provide a therapeutic synergistic effect.
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Cerebral isChemia, CalCium, and exCitotoxiCity
Van Harreveld (1970) and Rothman and Olney (1986) showed a 
glutamate release during asphyxia and demonstrated that excitatory 
aminoacids can cause neuronal damage. After asphyxia and release 
of excitatory neurotransmitters, the reserves of calcium within the 
endoplasmic reticulum of the cell can be released into the cytoplasm 
increasing intracellular levels (Taylor, 1987). Calcium imbalance 
within the cell can lead to cell death (Carafoli, 1987).
In normal situations, endoplasmic reticulum and mitochon-
dria sequesters calcium when intracellular levels increase, but 
during anoxia or ischemia, calcium levels increase within cells 
because calcium regulation depends on ATP and oxygen (Siesjo, 
1988). Calcium enters the cell through voltage-sensitive cal-
cium channels and agonist-operated calcium channels (Zhang 
et al., 1993). Agonist-operated calcium channels are activated 
by glutamate, N-methyl-d-aspartate (NMDA) and kainate, 
and quisqualate (K/Q). In the K/Q channel, calcium allows the 
entry of sodium and the output of potassium from the cell. 
NMDA receptors leads to calcium entry into cells and these are 
blocked by magnesium and stimulated by glycine (Foster and 
Fagg, 1987).
When oxygen and blood flow decreases to the brain, an ischemic 
cascade takes place. ATP decreases, cellular metabolism turns in 
to anaerobic glycolysis leading to an increase in hydrogen, phos-
phate, and lactate, culminating in intracellular acidosis. Hydrogen 
displaces calcium from intracellular proteins and intracellular 
calcium levels increase. There is a dysfunction of Na/K ATP-
dependent pump and ATP-dependent channels, such as calcium, 
Na, and K channels, stop functioning, this limits the calcium out-
put from the cell and the levels of intracellular calcium further 
increase. As calcium increases mitochondria sequesters it, leading 
to  mitochondrial dysfunction.
introduCtion
Therapeutic hypothermia (TH) is one of the wonders of medi-
cine. Although TH has gained interest as a therapeutic measure 
in recent years, it is a very old method. The use of TH in modern 
clinical medicine has been documented over the past 200 years. 
Hypothermia was widely used in ancient times; however, due to 
the ignorance of the adverse effects and the lack of controlled clini-
cal trials, the use of TH began to fall in the late 70s (Varon and 
Acosta, 2008).
The advent of numerous studies and controlled clinical trials 
began to emerge later and the interest in the use of hypothermia 
as a therapeutic measure arouse again (Bernard et al., 2002). TH 
is nowadays one of the most important methods of neuroprotec-
tion. It is well known that the use of TH improves neurological 
outcome in a variety of clinical scenarios such as post-cardiac 
arrest (Hypothermia after Cardiac Arrest Study Group, 2002), trau-
matic brain injury (TBI; The Brain Trauma Foundation, 2007), 
spinal cord injury (Dietrich, 2009), and it has been used in other 
diseases where it has proven to be useful as well such as a stroke 
(Yenari and Hemmen, 2010) and acute liver failure (Stravitz and 
Larsen, 2009).
Understanding the mechanisms of action through which TH 
provides neuroprotection will allow a better understanding about 
the indications for this therapy (Table 1), search for other thera-
pies when used in conjunction with hypothermia will provide a 
therapeutic synergistic effect and the emergence of more clinical 
trials demonstrating the utility of this therapy in other diseases as 
well (Alzaga et al., 2006).
The aim of this review is to present the molecular mechanisms 
of action of TH in the brain, understanding the events that occur 
after an episode of cerebral ischemia, and how hypothermia can 
affect the various steps of this cascade.
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Another mechanism by which hypothermia promotes survival 
of neurons is through an interaction on glycine. Excitatory ami-
noacids act on the NMDA receptor, increasing calcium influx into 
the cell. The NMDA receptor requires the presence of glycine to be 
activated, the presence of glycine accelerates the function of these 
receptors (Johnson and Ascher, 1987). TH significantly decreases 
brain glycine levels after ischemia, thus decreasing hyperexcitability 
by glutamate (Baker et al., 1991; Kvrivishvili, 2002).
Glycine and glycine receptor are fields of therapeutic action that 
have been studied previously. Glycine receptor antagonist drugs 
have been developed with poor results (Russell and Laverty, 2001). 
Nanoparticle formulations to antagonize the glycine site on the 
NMDA receptor have been created and may be a promising thera-
peutic measure and the role they can play as a combined therapy 
with TH is a very interesting field to explore (Sopala et al., 2002).
The interaction TH plays with nerve growth factors is 
another mechanism by which TH promotes neuronal survival. 
Neurotrophins are a group of neuronal growth and survival fac-
tors and brain-derived neurotrophic factor (BDNF) is the major 
neurotrophin studied. BDNF affects a known mitogen-activated 
enzymatic pathway protein kinase, the ERK, and through this enzy-
matic pathway, neurotrophins preserve neuronal integrity after the 
ischemic insult (Kokaia et al., 1993). Hypothermia reduces neuronal 
damage because significantly increases levels of BDNF and other 
neurotrophins after ischemic injury (D’Cruz et al., 2002; Vosler 
et al., 2005; Huang et al., 2008). Hypothermia may also stimulate 
angiogenesis in ischemic areas, a beneficial effect due to the activa-
tion of BDNF (Xie et al., 2007).
The field of action of nerve growth factors has been previously 
measured in experimental studies as a therapeutic target. BDNF 
has been used intravenously and intraventricular in focal and glo-
bal ischemia models (Schabitz et al., 1997, 2000). The results have 
been favorable, BDNF decreases the degree of neuronal damage 
and the infarction size. Finally, experimental reports have tested 
the synergy of hypothermia and BDNF in ischemia models. The 
results have been impressing, leading to a reduction of the infarct 
size up to 40% (Berger et al., 2004).
Finally, it is important to mention that TH also promotes neu-
ronal integrity through a mechanism of action on astroglial cells. 
After an ischemic insult, while neurons perform cell necrosis, glial 
cells survive to ischemia, experience hypertrophy and an activation 
process making them more responsive to immunologic stimuli. 
Astroglial cells proliferate, transform in to phagocytes, migrate, and 
release pro-inflammatory cytokines and free radicals. These cells 
can be cytotoxic (Gehrmann et al., 1992). Protein S-100B, which 
is found in astroglial cells, is a serum marker of poor neurologic 
outcome in patients undergoing hypothermia after cardiac arrest 
(Rundgren et al., 2009). Hypothermia avoids the proliferation, 
migration, transformation, and activation of astroglial cells after 
the ischemic insult (Hachimi-Idrissi et al., 2004).
hypothermia and apoptosis
Two types of cell death exist: necrotic cell death and programmed 
cell death, also known as apoptosis. Necrosis is a form of cell death 
where edema and cellular inflammatory response occur, leading to 
sudden death. Apoptosis is caused by a connection between intra-
cellular enzyme pathways; it is the culmination of an interaction 
Subsequently calcium activates intracellular proteases and 
 depolarization occurs in the cell membrane, releasing a large number 
of excitatory neurotransmitters such as glutamate, activating K/Q and 
NMDA receptors persistently (Leker and Shohami, 2002). The activa-
tion of these receptors leads to an influx of sodium and chloride into 
the postsynaptic cell, causing an intracellular hyperosmolarity, and an 
influx of water into the cell, resulting in intracellular edema and neu-
ronal death. At the same time, sodium influx inhibits the normal mag-
nesium blockade on NMDA receptors, making them more responsive 
to glutamate, which stimulates calcium entrance and neuronal death. 
Furthermore, glutamate has been recognized as a neurotoxin, causes 
hyperexcitability even after restoring the blood flow after ischemia, this 
is better known as “Exitotoxic Cascade” (Small et al., 1999).
meChanisms of aCtion of therapeutiC hypothermia
hypothermia and neuronal integrity
There are many mechanisms by which TH maintains the integrity 
of neurons and promotes the survival of these cells (Figure 1). 
After cerebral ischemic insult, a significant elevation in extracellular 
glutamate and other excitatory neurotransmitters such as aspartate 
occurs, leading to neuronal death (Benveniste et al., 1984). The 
integrity of neurons depends on the quantities of these neuro-
transmitters, so that greater amounts, the more neuronal damage 
(Globus et al., 1988). Hypothermia significantly reduces extracel-
lular levels of excitatory neurotransmitters, including dopamine 
and glutamate (Okuda et al., 1986). The release of these neuro-
transmitters is temperature dependent, and it was demonstrated 
that even mild levels of hypothermia exerts an inhibitory effect 
(Illievich et al., 1994; Ooboshi et al., 2000).
Table 1 | The mechanisms of action of therapeutic hypothermia.
Reduces extracellular levels of excitatory neurotransmitters
Decreases brain glycine levels after ischemia
Increases levels of BDNF and other neurotrophins after ischemic injury
Avoids the proliferation, migration, transformation, and activation of 
astroglial cells
Decreases p53 protein levels in the brain and apoptotic neuronal death
Affects the levels of proteins Bcl-2 and cytochrome C
Blocks the TNF pathway of apoptosis
Affects stress-activated signaling pathways avoiding cell apoptosis
Prevents apoptosis by inhibiting the caspase pathway
Blocks the proteins responsible for mediating the caspase-independent 
apoptosis
Induces the formation cold shock proteins
Lowers lactate levels from anaerobic metabolism decreasing 
cellular acidosis
Improves brain glucose metabolism and preserves glucose 
reserves in the brain
Reduces free radical levels after neuronal damage
Blocks delta-PKC and preserves function of Epsilon-PKC after ischemia
Reinforces Akt pathway and carries out structural alterations in PTEN
Decreases production of inflammatory cytokines and leukotrienes
Decreases inflammatory cells function such as macrophages
Suppress epileptogenic electrical activity
Reduces disruption of the blood–brain barrier
Decreases damage of the endothelial vasculature
Decreases the concentrations of thromboxane A2
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domain (TRADD) and Fas-associated protein with death domain 
(FADD) are adapter proteins which can interact with TNF recep-
tors allowing the apoptotic signal to continue (Zhang and Winoto, 
1996). The induction of TNF apoptotic pathway has been described 
in TBI and is one of the most important pathway mediating neu-
ronal apoptosis. TNF receptors can trigger apoptosis because of an 
activation of pro-apoptotic transcription factors such as NFkB and 
AP-1 (Morganti-Kossmann et al., 1997). There are experimental 
studies in where TH has demonstrated to block the TNF pathway 
of apoptosis, its receptors such as FasL, Fas, TNFR1, and the fol-
lowing events that culminate in cell death (Liu et al., 2008). The 
TNF pathway of apoptosis is a promising area of study.
Another important pathway in neuronal apoptosis is the stress-
activated signaling pathways in which hypothermia exerts also a 
mechanism of action. Many regulatory pathways within the cell 
exist, working as intermediaries to control processes of prolif-
eration, differentiation, and apoptosis. Protein kinases are the 
most recognized group of these proteins. They can travel to the 
nucleus modifying the expression of genes in DNA. Three groups 
of protein kinases are the most important: mitogen- activated 
protein kinase (MAPK), mitogen-activated protein kinase kinase 
(MAPKK), and mitogen-activated protein kinase kinase kinase 
(MAPKKK; Pawton, 1995). Each of these proteins are  constituted 
between pro-apoptotic and antiapoptotic proteins (Mattson et al., 
2000). It is a programmed intracellular process which leads to cell 
death. TH inhibits apoptotic neuronal death because decreases p53 
protein levels in the brain, a cellular transcription factor which 
activates genes of apoptosis and pro-apoptotic proteins, includ-
ing Bak, Bax, and PUMA (Bargonetti and Manfredi, 2002; Ji et al., 
2007; Figure 2).
The Bcl-2 family is a group of apoptotic proteins. Some of them 
such as Bcl-XL, Bcl-W, and Bcl-2 have antiapoptotic properties, 
whereas others, such as Bak, Bax, Bok, and Bid have pro-apop-
totic properties (Reed, 1998). If pro-apoptotic proteins are acti-
vated, they lead to the formation of pores in the mitochondria’s 
membrane, allowing the release of cytochrome C to the cytosol, 
activating caspases, culminating in neuronal death. Hypothermia 
beneficially affects the levels of proteins Bcl-2 and cytochrome C 
after the ischemic insult, notwithstanding there is few other reports 
that suggest otherwise (Bossenmeyer-Pourie et al., 2000; Khar et al., 
2003; Zhao et al., 2004).
Another pathway that also triggers the process of apoptosis is the 
TNF pathway. TNF through its receptors can initiate several routes 
(such as caspases) and culminate in apoptosis. These receptors are 
the Fas ligand (FasL), Fas (CD95), the complex of TNFR1 and 2, and 
many others (Brunner et al., 1995). TNF receptor-associated death 
 
Figure 1 | Mechanisms by which therapeutic hypothermia (TH) maintains 
neuronal integrity after cerebral ischemia. TH blocks the release of excitatory 
neurotransmitters such as glutamate, aspartate, and dopamine, inhibits the 
action of glycine in the NMDA receptor, increases angiogenesis, and inhibits 
ERK pathway by stimulating the formation of BDNF. TH also avoids 
the transformation and activation of astroglial cells after ischemia. TH, 
therapeutic hypothermia; NMDA, N-methyl-d-aspartate; BDNF, brain-derived 
neurotrophic factor.
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and 7. They stimulate release of cytochrome C from mitochondria 
leading to apoptosis (Muzio et al., 1998). Experimental models have 
shown that TH strongly inhibits the caspases pathway preventing 
apoptosis. The effect of hypothermia in theses pathways is such that 
makes it probably the therapeutic measure with the most benefit 
preventing neuronal apoptosis (Zhao et al., 2004; López-Hernández 
et al., 2006; Schmitt et al., 2007).
Other pathways and proteins cause apoptosis without directly 
involving the caspases, for example, a protein called apoptosis 
inducing factor (AIF) located in the mitochondrial membrane. 
When this protein is released by the mitochondria, travels to the 
nucleus and performs a DNA fragmentation culminating in cell 
death (Susin et al., 1999). There are other families of proteins called 
calpaines, cathepsines, and granzymes. Located inside the lyso-
somes, cathepsin degrades collagen, fibronectin, and proteoglycans. 
Granzymes can lead to DNA fragmentation (Shi et al., 1992). TH 
blocks all these proteins responsible for mediating the caspase-
independent apoptosis and this is also an interesting field of study 
(Zhao et al., 2007).
After cerebral ischemia there is an important increase in some 
pro-apoptotic proteins such as the delta-PKC. This is a protein that 
belongs to the protein kinase C (PKC) family and plays an impor-
tant role in neuronal death (Bright et al., 2004). Delta-PKC is acti-
vated by caspase-3 after which induces mitochondrial dysfunction, 
or travels to the nucleus to induce apoptosis (Raval et al., 2005). 
by sub-families; for example in the MAPK, there are the extracel-
lular signal-regulated kinase (ERK), c-Jun-N-terminal protein 
kinase (JNK), and p38. These proteins constitutes the major 
stress-activated signaling pathways and the role of these intra-
cellular regulators is very important, trying to maintain cellular 
homeostasis (Schaeffer and Weber, 1999). There are experimen-
tal studies in where hypothermia affects these routes, avoiding 
consequently cell apoptosis. The stress-activated signaling path-
ways are an important target of study (Schmitt et al., 2007; Yang 
et al., 2009).
Hypothermia exerts also has a mechanism of action on one of 
the most important pathways in the process of apoptosis, the cas-
pases pathway. This pathway is the point in where many of the other 
vias meet, caspases are the final pathway which directly “executes” 
the cell. Caspases are among the largest and most important path-
ways responsible for apoptosis. There are two principal apoptotic 
pathways mediated by caspases: Intrinsic and Extrinsic pathway. 
The intrinsic pathway is known to be activated by cellular stress 
such as radiation, hypoxia, and substrate deprivation. When the cell 
is subjected to one of these stressors, the substrate MMP is formed, 
this substrate acts at the mitochondria allowing the release of 
Cytochrome C, which interacts with another substrate, the Apaf-1, 
eventually leading to the activation of caspases 9 and 3, culminating 
in cell death (Kuida, 2000). The extrinsic pathway is activated by 
Fas-FasL, TNF-TNFR1 and leads to the activation of caspase-8, 3, 6, 
 
Figure 2 | Mechanisms by which therapeutic hypothermia (TH) avoids 
apoptosis. TH blocks the TNF pathway and, increases the levels of CIRP; it inhibits 
the P38, JNK, and ERK pathways. TH avoids apoptosis directly by inhibition of the 
caspases pathway, blocking caspases 8, 3, 6, 7, 9, and cytochrome C. TH also 
blocks the P53 protein and affects the Bcl-2 family, blocking pro-apoptotic proteins 
such as Bax, Bak, Bok, Bid, Delta-PKC, PTEN, AIF, P38, JNK, ERK, granzymes, and 
reinforcing Epsilon-PKC, Bcl-2, Bcl-XL and Bcl-W, and AKT pathway. TH also avoids 
degradation of collagen, fibronectin, and proteoglycans by blocking cathepsines. 
TH, therapeutic hypothermia; TNF, tumor necrosis factor; CIRP, cold-inducible 
RNA-binding protein; TRADD, TNF receptor-associated death domain; FADD, 
Fas-associated protein with death domain; ERK, extracellular signal-regulated 
kinase; JNK, C-Jun-N-terminal protein kinase; AIF: apoptosis inducing factor.
www.frontiersin.org February 2011 | Volume 2 | Article 4 | 5
González-Ibarra et al. Therapeutic hypothermia
hypothermia and metabolism
After the cerebral blood flow decreases, metabolism turns in to 
anaerobic metabolism and intracellular levels of hydrogen, phos-
phate, and lactate increase creating intra and extracellular acidosis. 
In the absence of ATP, there is mitochondrial dysfunction and cell 
death. Hypothermia is likely to lower lactate levels and other wastes 
from anaerobic metabolism decreasing cellular acidosis (Jiang et al., 
2004; Figure 3).
Rosomoff and Holaday (1954) first described that hypother-
mia decreased cerebral blood flow and oxygen consumption, 
he also showed this effect was proportional to the depth of 
hypothermia. It is now established that hypothermia decreases 
cerebral blood flow along with cerebral oxygen consumption, 
glucose utilization, and brain metabolism, so this decrease is 
not deleterious. Brain metabolism decreases in range of 5–6% 
or even up to 10% for every degree decrease in temperature 
(Hagerdal et al., 1975). Hypothermia can also improve brain 
glucose metabolism and preserves glucose reserves in the brain, 
so they can be used even days after brain damage (Kimura 
et al., 2002).
Finally, after ischemia or TBI, there is an increased production 
of thromboxane A2 (TXA2) which is a potent vasoconstrictor, 
stimulates platelet aggregation and could lead to vessel occlusion 
(Dogné et al., 2004). Hypothermia decreases the concentrations 
Epsilon-PKC unlike delta-PKC is another protein which shows 
antiapoptotic properties, but is degraded by caspases after the 
ischemic insult. Hypothermia acts in both proteins, blocking the 
translocation to the mitochondria and the nucleus of delta-PKC 
and stimulating the preservation of the action of Epsilon-PKC after 
ischemia (Shimohata et al., 2007a,b).
Another important antiapoptotic molecule is the Akt. In order 
to exerts an antiapoptotic function, this molecule needs to be phos-
phorylated, but PTEN which is a pro-apoptotic molecule, exerts 
its action by preventing the phosphorylation of Akt. Interestingly, 
these reactions can be regulated by free radicals (Zhao et al., 2006). 
Experimental models of ischemia have shown that hypothermia 
reduces the infarct size in experimental models of ischemia after 
reinforcement of Akt pathway, and can also carry out structural 
alterations in PTEN, decreasing apoptosis, thus protecting the cell 
(Zhao et al., 2005; Lee et al., 2009).
Finally some proteins, including cold-inducible RNA-binding 
protein (CIRP), are induced in the cells by a cold stimulus and have 
the capacity to stop apoptosis at many levels, providing cellular 
protection (Jones and Inouye, 1994). Mild hypothermia induces 
their formation and deep hypothermia avoids it. They act primarily 
in the processes of RNA transcription, but can also act in DNA and 
prevent free radical’s damage and can block apoptosis pathways 
such as the TNF-alpha pathway (Sakurai et al., 2006).
Figure 3 | Mechanisms by which therapeutic hypothermia (TH) affects the 
metabolism and oxidative stress. TH inhibits the formation of lactate, 
hydrogen, and phosphate, increases glucose reserves and metabolism of the 
neurons. TH also decreases the levels of TXA2 and prevents vessel occlusion. 
TH, therapeutic hypothermia; TXA2, thromboxane A2; OH– , hydroxyl radicals; 
O2
–, superoxide; H2O2: hydrogen peroxide.
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independently of diagnosis (Vespa et al., 1999). Hypothermia can 
 suppress epileptogenic electrical activity and is effective in both the 
NCSE and in cases of generalized tonic–clonic seizures. The combi-
nation of other available measures for NCSE and generalized tonic–
clonic seizures with TH as a synergistic therapy after stroke or TBI is 
another interesting field research (Corry et al., 2008).
reCommendations for future studies
Knowing the multiple mechanisms of action of TH at the molecular 
level has a very ample clinical relevance because we strongly believe 
it would allow in the future, firstly the emergence of more controlled 
clinical trials that combine other existing therapies for neuroprotection 
with hypothermia searching for synergies and favorable neurological 
outcomes. Secondly the development of new drugs for some specific 
pathways of the cascade of ischemia that may in the same way exert a 
synergistic effect with hypothermia and provide neuroprotection.
Some therapies have been tested previously in experimental 
models. For example the combination of TH with neuronal growth 
factors, especially BDNF. This combination therapy has shown 
impressive results in animal models (Berger et al., 2004).
Among other possible combination therapies to find a synergis-
tic therapeutic effect we can mention the use of the nanoparticle 
formulations to antagonize the glycine site on the NMDA receptor 
or glycine receptor antagonist along with TH.
Other possible synergistic combinations are the association 
of TH with TNF antagonists, free radical and thromboxane A2 
antagonists, drugs developed specifically to block several pathways 
of apoptosis such as caspases pathway, among others. Similarly, the 
combination of TH with other therapeutic measures commonly 
used to reduce intracranial pressure after TBI and antiepileptic 
drugs used in seizures or NCSE after TBI or stroke.
ConClusion
Therapeutic hypothermia is one of the most important therapies 
for providing neuroprotection. Its use in different clinical scenarios 
such as post-cardiac arrest, TBI, stroke, among others is increasingly 
being more used. The mechanisms of action of TH are multiple 
and varied. TH can affect many metabolic pathways, reactions of 
inflammation, apoptosis processes, among many other pathways. 
The possible explanation for the benefits and the success of this 
therapy is probably the multiple mechanisms of action blocking 
the cascade of ischemia on many levels.
We strongly believe that the use of TH will continue to increase in 
various clinical settings. Although most of the studies supporting the 
benefits of TH are experimental studies in animal models, the emer-
gence of more controlled clinical trials evaluating synergistic effects 
of TH in association with other therapies will allow a widespread 
use of this therapy. The field of research of TH is very ample.
of thromboxane A2 in experimental models of head trauma and 
ischemia. This may be a potential experimental target specially in 
patients under TH after TBI (Aibiki et al., 2000).
hypothermia, oxidative stress, and inflammation
Free radicals are oxygen derived compounds. They are extremely 
reactive and can produce cellular damage when acts in DNA, lipid 
membranes, proteins and enzymes. These compounds play an impor-
tant role in brain damage after ischemia and TBI (Peters et al., 1998). 
Free radicals can come from arachidonic acid, nitric oxide, catecho-
lamines, glutamate, and activation of NMDA receptors. Examples 
of these radicals are hydroxyl radicals (OH–), superoxide (O
2
–), and 
hydrogen peroxide (H
2
O
2
; Beckman et al., 1990; Globus et al., 1995a). 
Globus was the first to demonstrate the formation of free radicals after 
ischemic damage and that this production was temperature dependent. 
Hypothermia significantly reduces free radical levels after neuronal 
damage (Figure 3). The combination of specific free radicals antago-
nists and hypothermia may be a potential synergistic combination and 
thus a field of study (Globus et al., 1995b; Horiguchi et al., 2003).
Along with free radicals production, after an ischemic insult, 
inflammatory mechanisms emerge and may last hours to several 
days. This is a normal physiological response; there are cytokines 
that have been shown to be protective and other cytokines that are 
deleterious such as TNF-alpha and IL-1Beta (Merrill and Benveniste, 
1996). Hypothermia decreases the production of inflammatory 
cytokines, leukotrienes, and inflammatory cells function such as 
macrophages (Kimura et al., 2002; Xiong et al., 2009).
hypothermia, intraCranial hypertension, and brain 
eleCtriCal aCtivity
After ischemia or TBI there is a disruption in the integrity of cell 
membranes and an increased permeability of endothelial cells, so 
the blood–brain barrier is lost in some level. This allows the devel-
opment of cerebral edema leading to intracranial hypertension 
(Stocchetti et al., 2007). When intracranial hypertension devel-
ops it is important to treat the cause behind this rather than the 
result. Hypothermia decreases the cytotoxic edema formed after 
TBI, reduces disruption of the blood–brain barrier, and decreases 
the damage of the endothelial vasculature. Some authors claim that 
hypothermia is probably nowadays the best measure for intracra-
nial hypertension after TBI. The combination of other available 
measures for intracranial hypertension with TH as a synergistic 
therapy is another potential field of action and research (Chi et al., 
2001; McIntyre et al., 2003; González et al., 2009).
Another complication after stroke or TBI is non-convulsive status 
epilepticus (NCSE). NCSE is an electroencephalographic evidence of 
continuous seizure activity in a patient without motor convulsions. 
The presence of NCSE is associated with high morbidity and  mortality, 
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